Navigation Links
Specialty Drug Delivery Firm Integral BioSystems LLC to Participate in Contract Pharma Magazine’s 12th Annual Contracting & Outsourcing Conference & Tabletop Exhibition
Date:7/30/2013

Bedford, Massachusetts (PRWEB) July 30, 2013

Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D., will offer potential clients advice on the use of Integral’s novel, platform front-of-the-eye and back-of-the-eye ophthalmic therapeutic delivery systems, OcuSurf™ and EySite™.

Integral BioSystems’ niche is in nano-engineered drug delivery systems aimed at providing solutions to long-held issues in drug products, especially in low drug absorption by target tissues due to cell impermeability and insolubility. In addition to assisting drug companies in developing their dosage forms, Integral scientists are also working on novel solutions to improve the bioavailability of Class II, III and IV compounds.

The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.

Once the drug-containing formulations are tested in preclinical models, the Company develops an integrated CMC plan to systematically transition the project to scale up and product development. As part of product development, Integral BioSystems specializes in efficiently developing a dosage form to manufacture and test in Phase I/Phase II first-in-man trials for proof-of-concept. The Company has a network of manufacturers/analytical houses for pharmaceutics that can fast-track the manufacture and release of the sterile dosage form for first-in-man trials.

About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. The Company business model is based on the following corporate objectives: (a) to be a collaborating partner in formulation development/drug product design for start-up and small companies, taking concepts from the laboratory to the clinic, (b) to re-formulate approved drugs for better efficacy and safety profiles, (c) to be a collaborating partner with API synthesis companies to develop generic drug product formats and (d) offer corporate legal services such as contract development/negotiations, patent filings and assessment of IP portfolios.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10980225.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Book Presents Strategies to Improve Patient Outcomes and Control Soaring Specialty Rx Costs
2. SafeToSleep and Brixy Announce Exclusive Program for Brixy Specialty Retailers
3. AJ Palutis and Fred Hait Receive Workers' Compensation Law Specialty Certification
4. Study finds racial and ethnic disparities in usage of specialty services for children with autism
5. ‘2-Hour Patient Acceptance Guarantee’ Program from BioPlus Specialty Pharmacy Rolls Out to Enthusiastic Physician and Patient Response
6. Specialty Technical Publishers (STP) Partners with AECOM to Advance Global EHS Auditing Solutions for Companies
7. BioPlus Specialty Pharmacy Founder and CEO Selected as Finalist in Ernst & Young Florida Entrepreneur of the Year Award
8. U.S. Specialty Films Market Worth $8 Billion & Packaging Drives Industry by 2017 Says New Research Report at ReportsnReports.com
9. Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar
10. Nationally-Recognized Retinal Expert Returns to Gainesville, Joins Retina Specialty Institute
11. Lourdes Specialty Hospital Offers Unique Treatment Option for Medically Complex Patients with Hyperbaric Oxygen Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable ... that visits to the dentist fit into their patients’ busy lifestyles. Dental365 also ...
(Date:6/23/2017)... CA (PRWEB) , ... June 23, 2017 , ... By ... earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ... the top 1% of all charities reviewed by Charity Navigator and earns ANRF a ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend ... entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger to ... years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Cancer Conference from Sept. 18 to 20. , The two-day conference is focused ... with the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/13/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... Food and Drug Administration (FDA) has notified the Company that ... Zhejiang, China manufacturing facility has been ... clearance of the Warning Letter related to our ... of the progress we have made in our ongoing quality ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology: